Plasma fractionation issues

Albert Farrugia, Theo Evers, Pierre Francois Falcou, Thierry Burnouf, Luiz Amorim, Sylvia Thomas

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Procurement and processing of human plasma for fractionation of therapeutic proteins or biological medicines used in clinical practice is a multi-billion dollar international trade. Together the private sector and public sector (non-profit) provide large amounts of safe and effective therapeutic plasma proteins needed worldwide. The principal therapeutic proteins produced by the dichotomous industry include gamma globulins or immunoglobulins (including pathogen-specific hyperimmune globulins, such as hepatitis B immune globulins) albumin, factor VIII and Factor IX concentrates. Viral inactivation, principally by solvent detergent and other processes, has proven highly effective in preventing transmission of enveloped viruses, viz. HBV, HIV, and HCV.

Original languageEnglish
Pages (from-to)88-93
Number of pages6
JournalBiologicals
Volume37
Issue number2
DOIs
Publication statusPublished - Apr 2009
Externally publishedYes

Fingerprint

Fractionation
Immunoglobulins
Plasma (human)
Proteins
Plasmas
International trade
gamma-Globulins
Globulins
Factor VIII
Pathogens
Viruses
Detergents
Virus Inactivation
Medicine
Blood Proteins
Albumins
Private Sector
Public Sector
Hepatitis B
Industry

Keywords

  • Factor VIII
  • IVIG
  • Procurement of plasma
  • Protein fractionation
  • Viral inactivation

ASJC Scopus subject areas

  • Biotechnology
  • Applied Microbiology and Biotechnology
  • Bioengineering
  • Immunology and Microbiology(all)
  • Pharmacology

Cite this

Farrugia, A., Evers, T., Falcou, P. F., Burnouf, T., Amorim, L., & Thomas, S. (2009). Plasma fractionation issues. Biologicals, 37(2), 88-93. https://doi.org/10.1016/j.biologicals.2009.01.005

Plasma fractionation issues. / Farrugia, Albert; Evers, Theo; Falcou, Pierre Francois; Burnouf, Thierry; Amorim, Luiz; Thomas, Sylvia.

In: Biologicals, Vol. 37, No. 2, 04.2009, p. 88-93.

Research output: Contribution to journalArticle

Farrugia, A, Evers, T, Falcou, PF, Burnouf, T, Amorim, L & Thomas, S 2009, 'Plasma fractionation issues', Biologicals, vol. 37, no. 2, pp. 88-93. https://doi.org/10.1016/j.biologicals.2009.01.005
Farrugia A, Evers T, Falcou PF, Burnouf T, Amorim L, Thomas S. Plasma fractionation issues. Biologicals. 2009 Apr;37(2):88-93. https://doi.org/10.1016/j.biologicals.2009.01.005
Farrugia, Albert ; Evers, Theo ; Falcou, Pierre Francois ; Burnouf, Thierry ; Amorim, Luiz ; Thomas, Sylvia. / Plasma fractionation issues. In: Biologicals. 2009 ; Vol. 37, No. 2. pp. 88-93.
@article{63ac664112224f5ebe6ee9d32728fbd2,
title = "Plasma fractionation issues",
abstract = "Procurement and processing of human plasma for fractionation of therapeutic proteins or biological medicines used in clinical practice is a multi-billion dollar international trade. Together the private sector and public sector (non-profit) provide large amounts of safe and effective therapeutic plasma proteins needed worldwide. The principal therapeutic proteins produced by the dichotomous industry include gamma globulins or immunoglobulins (including pathogen-specific hyperimmune globulins, such as hepatitis B immune globulins) albumin, factor VIII and Factor IX concentrates. Viral inactivation, principally by solvent detergent and other processes, has proven highly effective in preventing transmission of enveloped viruses, viz. HBV, HIV, and HCV.",
keywords = "Factor VIII, IVIG, Procurement of plasma, Protein fractionation, Viral inactivation",
author = "Albert Farrugia and Theo Evers and Falcou, {Pierre Francois} and Thierry Burnouf and Luiz Amorim and Sylvia Thomas",
year = "2009",
month = "4",
doi = "10.1016/j.biologicals.2009.01.005",
language = "English",
volume = "37",
pages = "88--93",
journal = "Biologicals",
issn = "1045-1056",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Plasma fractionation issues

AU - Farrugia, Albert

AU - Evers, Theo

AU - Falcou, Pierre Francois

AU - Burnouf, Thierry

AU - Amorim, Luiz

AU - Thomas, Sylvia

PY - 2009/4

Y1 - 2009/4

N2 - Procurement and processing of human plasma for fractionation of therapeutic proteins or biological medicines used in clinical practice is a multi-billion dollar international trade. Together the private sector and public sector (non-profit) provide large amounts of safe and effective therapeutic plasma proteins needed worldwide. The principal therapeutic proteins produced by the dichotomous industry include gamma globulins or immunoglobulins (including pathogen-specific hyperimmune globulins, such as hepatitis B immune globulins) albumin, factor VIII and Factor IX concentrates. Viral inactivation, principally by solvent detergent and other processes, has proven highly effective in preventing transmission of enveloped viruses, viz. HBV, HIV, and HCV.

AB - Procurement and processing of human plasma for fractionation of therapeutic proteins or biological medicines used in clinical practice is a multi-billion dollar international trade. Together the private sector and public sector (non-profit) provide large amounts of safe and effective therapeutic plasma proteins needed worldwide. The principal therapeutic proteins produced by the dichotomous industry include gamma globulins or immunoglobulins (including pathogen-specific hyperimmune globulins, such as hepatitis B immune globulins) albumin, factor VIII and Factor IX concentrates. Viral inactivation, principally by solvent detergent and other processes, has proven highly effective in preventing transmission of enveloped viruses, viz. HBV, HIV, and HCV.

KW - Factor VIII

KW - IVIG

KW - Procurement of plasma

KW - Protein fractionation

KW - Viral inactivation

UR - http://www.scopus.com/inward/record.url?scp=63249113806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63249113806&partnerID=8YFLogxK

U2 - 10.1016/j.biologicals.2009.01.005

DO - 10.1016/j.biologicals.2009.01.005

M3 - Article

VL - 37

SP - 88

EP - 93

JO - Biologicals

JF - Biologicals

SN - 1045-1056

IS - 2

ER -